Advancing cancer treatment: in vivo delivery of therapeutic small noncoding RNAs

Xiaoyue Yang; Ying Liang; Sheng Tong

doi:10.3389/fmolb.2023.1297413

Advancing cancer treatment: in vivo delivery of therapeutic small noncoding RNAs

Front Mol Biosci. 2024 Jan 3:10:1297413. doi: 10.3389/fmolb.2023.1297413. eCollection 2023.

Authors

Xiaoyue Yang¹, Ying Liang², Sheng Tong¹

Affiliations

¹ F. Joseph Halcomb III, MD Department of Biomedical Engineering, University of Kentucky, Lexington, KY, United States.
² New York Blood Center, New York, NY, United States.

Abstract

In recent years, small non-coding RNAs (ncRNAs) have emerged as a new player in the realm of cancer therapeutics. Their unique capacity to directly modulate genetic networks and target oncogenes positions them as valuable complements to existing small-molecule drugs. Concurrently, the advancement of small ncRNA-based therapeutics has rekindled the pursuit of efficacious in vivo delivery strategies. In this review, we provide an overview of the most current clinical and preclinical studies in the field of small ncRNA-based cancer therapeutics. Furthermore, we shed light on the pivotal challenges hindering the successful translation of these promising therapies into clinical practice, with a specific focus on delivery methods, aiming to stimulate innovative approaches to address this foundational aspect of cancer treatment.

Keywords: cancer; in vivo delivery; miRNA; siRNA; small non-coding RNA.

Publication types

Review

Abstract

Publication types

Grants and funding